Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: An Eastern Cooperative Oncology Group Study Seena C. Aisner, MD, Suzanne Dahlberg, PhD, Meera R. Hameed, MD, David S. Ettinger, MD, Joan H. Schiller, MD, David H. Johnson, MD, Joseph Aisner, MD, Patrick J. Loehrer, MD Journal of Thoracic Oncology Volume 5, Issue 6, Pages 885-892 (June 2010) DOI: 10.1097/JTO.0b013e3181d86a30 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Progression-free survival by epidermal growth factor receptor (EGFR) group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Progression-free survival by C-Kit group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 3 Overall survival by epidermal growth factor receptor (EGFR) group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 4 Overall survival by C-kit group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions